Caris Life Sciences financials
$31.55−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY15 Jun 30 | FY14 Jun 30 | FY13 Jun 30 | FY12 Jun 30 | FY11 Jun 30 | FY10 Jun 30 |
|---|---|---|---|---|---|---|---|
| Revenue | $812.0M | $3.31B | $3.56B | $3.68B | $3.77B | $3.58B | $3.15B |
| Gross profit | $539.2M | $1.12B | $1.14B | $1.15B | $1.18B | $1.05B | $941.6M |
| Gross margin | 66.4% | 33.8% | 31.9% | 31.1% | 31.1% | 29.3% | 29.9% |
| Operating income | $45.1M | $236.4M | $257.4M | $270.8M | $299.8M | $251.4M | $194.8M |
| Net income | -$538.0M | $126.2M | $135.3M | $151.7M | $167.5M | $144.2M | $106.5M |
| Net margin | −66.2% | 3.8% | 3.8% | 4.1% | 4.4% | 4.0% | 3.4% |
| Diluted EPS | $-3.22 | $5.17 | $5.38 | $6.35 | $5.96 | $4.61 | $3.47 |
| EBITDA | $67.7M | $302.5M | $322.6M | $324.9M | $355.8M | $307.5M | $247.8M |
| Operating cash flow | $83.2M | $226.9M | $203.5M | $249.3M | $271.2M | $231.2M | $209.3M |
| Free cash flow | $66.9M | $209.4M | $188.2M | $233.9M | $252.9M | $216.8M | $186.8M |
| Diluted shares | 167.2M | 24.4M | 25.2M | 23.9M | 28.1M | 31.3M | 30.7M |
Balance sheet
| Period end | Dec 31 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $797.8M | $35.4M | $64.5M | $64.3M | $15.7M | $164.8M |
| Short-term investments | $2.3M | — | — | — | — | — |
| Total debt | $379.0M | $1.06B | $1.28B | $596.3M | $534.8M | $409.9M |
| Total assets | $1.13B | $3.24B | $3.36B | $2.50B | $2.39B | $2.32B |
| Total liabilities | $548.4M | $1.76B | $2.00B | $1.29B | $1.22B | $1.01B |
| Shareholders' equity | $577.3M | $1.48B | $1.36B | $1.21B | $1.16B | $1.31B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology